Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Miami
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Janssen Research & Development, LLC
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Colorado, Denver
Hoosier Cancer Research Network
Beijing 302 Hospital
Chinese PLA General Hospital
Georgetown University
First People's Hospital of Hangzhou
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Mayo Clinic
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital of Soochow University
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
City of Hope Medical Center
M.D. Anderson Cancer Center
University of Nebraska
M.D. Anderson Cancer Center
Stemline Therapeutics, Inc.
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Groupe Francophone des Myelodysplasies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
St. Jude Children's Research Hospital
H. Lee Moffitt Cancer Center and Research Institute
Columbia University